Evaluation of the PROPEL® mini sinus implant for the treatment of frontal sinus disease

Document Type

Article

Abstract

Introduction: Propel and Propel Mini sinus implants are mometasone furoate-coated bioabsorbable stents used as an adjunct in the management of chronic rhinosinusitis after endoscopic sinus surgery. The original sinus implant was deployed in the ethmoid sinuses to provide medialization of the middle turbinate, decrease scarring and mucosal adhesions, limit polyp regrowth, and reduce mucosal inflammation. A structurally smaller version of the Propel, the Propel Mini, was developed and now has been approved for endoscopic placement in the frontal sinuses. Areas covered: This evaluation will focus on the technical details of the Propel mini, previous studies documenting Propel’s success in the ethmoid sinuses, and the safety and efficacy of the Propel mini implants in frontal sinus surgery. Expert opinion: Devices such as the Propel and Propel Mini stents are the beginning of a trend towards medication-coated bioabsorbable implants that can be used for sinonasal disease to minimize complications or possible side effects of surgical treatment by an increase of topical drug delivery locally.

Publication Date

12-1-2016

Publication Title

Expert Opinion on Drug Delivery

ISSN

17425247

E-ISSN

17447593

Volume

13

Issue

12

First Page

1789

Last Page

1793

PubMed ID

27758142

Digital Object Identifier (DOI)

10.1080/17425247.2016.1250740

This document is currently not available here.

Share

COinS